{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T21:06:00Z","timestamp":1777669560278,"version":"3.51.4"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100020898","name":"Universidade Federal de Ci\u00eancias da Sa\u00fade de Porto Alegre","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100020898","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["001"],"award-info":[{"award-number":["001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["422298\/2016-6"],"award-info":[{"award-number":["422298\/2016-6"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["310846\/2014-5"],"award-info":[{"award-number":["310846\/2014-5"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004263","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado do Rio Grande do Sul","doi-asserted-by":"publisher","award":["16\/2551-0000265-7"],"award-info":[{"award-number":["16\/2551-0000265-7"]}],"id":[{"id":"10.13039\/501100004263","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004263","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado do Rio Grande do Sul","doi-asserted-by":"publisher","award":["16\/2551-0000473-0"],"award-info":[{"award-number":["16\/2551-0000473-0"]}],"id":[{"id":"10.13039\/501100004263","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Neurobiol"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s10571-023-01338-4","type":"journal-article","created":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T17:03:04Z","timestamp":1681405384000},"page":"2939-2951","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Metastatic Melanoma: A Preclinical Model Standardization and Development of a Chitosan-Coated Nanoemulsion Containing Temozolomide to Treat Brain Metastasis"],"prefix":"10.1007","volume":"43","author":[{"given":"Nicolly Espindola","family":"Gelsleichter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priscila Oliveira","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernanda Cardoso","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela Nogueira","family":"Debom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela Spies","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela Gon\u00e7alves","family":"Roliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"de C\u00e1ssia Sant\u2019ana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernanda","family":"Visioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fl\u00e1via Nathiely Silveira","family":"Fachel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luana Roberta","family":"Michels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana Hofst\u00e4tter","family":"Azambuja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helder Ferreira","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizandra","family":"Braganhol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,13]]},"reference":[{"key":"1338_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12030251","author":"T Adnet","year":"2020","unstructured":"Adnet T et al (2020) Pharmacotechnical development of a nasal drug delivery composite nanosystem intended for alzheimer\u2019s disease treatment. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics12030251","journal-title":"Pharmaceutics"},{"key":"1338_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-019-01730-6","author":"JH Azambuja","year":"2020","unstructured":"Azambuja JH et al (2020) Nasal administration of cationic nanoemulsions as CD73-siRNA delivery system for glioblastoma treatment: a new therapeutical approach. Mol Neurobiol. https:\/\/doi.org\/10.1007\/s12035-019-01730-6","journal-title":"Mol Neurobiol"},{"key":"1338_CR4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.8539","author":"F Azimi","year":"2012","unstructured":"Azimi F et al (2012) Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2011.37.8539","journal-title":"J Clin Oncol"},{"key":"1338_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2009.09.015","author":"P Baldrick","year":"2010","unstructured":"Baldrick P (2010) The safety of chitosan as a pharmaceutical excipient. Regul Toxicol Pharmacol. https:\/\/doi.org\/10.1016\/j.yrtph.2009.09.015","journal-title":"Regul Toxicol Pharmacol"},{"issue":"12","key":"1338_CR6","first-page":"4799","volume":"30","author":"V Bobek","year":"2010","unstructured":"Bobek V et al (2010) A clinically relevant, syngeneic model of spontaneous, highly metastatic B16 mouse melanoma. Antiancer Res 30(12):4799\u20134803","journal-title":"Antiancer Res"},{"key":"1338_CR7","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0905139106","author":"D Bogunovic","year":"2009","unstructured":"Bogunovic D et al (2009) Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci USA. https:\/\/doi.org\/10.1073\/pnas.0905139106","journal-title":"Proc Natl Acad Sci USA"},{"key":"1338_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24234312","author":"FA Bruinsmann","year":"2019","unstructured":"Bruinsmann FA et al (2019) Nasal drug delivery of anticancer drugs for the treatment of glioblastoma: preclinical and clinical trials. Molecules. https:\/\/doi.org\/10.3390\/molecules24234312","journal-title":"Molecules"},{"key":"1338_CR9","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jcis.2010.09.073","volume":"353","author":"G Calder\u00f3","year":"2010","unstructured":"Calder\u00f3 G, Garc\u00eda-Celma M, Solans C (2010) Formation of polymeric nano-emulsions by a low-energy method and their use for nanoparticle preparation. J Colloid Interface Sci 353:406\u2013411. https:\/\/doi.org\/10.1016\/j.jcis.2010.09.073","journal-title":"J Colloid Interface Sci"},{"key":"1338_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.178","author":"V Chiarion-Sileni","year":"2011","unstructured":"Chiarion-Sileni V et al (2011) Central nervous system failure in melanoma patients: Results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine-based regimens. Br J Cancer. https:\/\/doi.org\/10.1038\/bjc.2011.178","journal-title":"Br J Cancer"},{"key":"1338_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19020255","author":"N Clemente","year":"2018","unstructured":"Clemente N et al (2018) \u2018Solid lipid nanoparticles carrying temozolomide for melanoma treatment. Preliminary in vitro and in vivo studies. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms19020255","journal-title":"Int J Mol Sci"},{"key":"1338_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25634","author":"MA Davies","year":"2011","unstructured":"Davies MA et al (2011) Prognostic factors for survival in melanoma patients with brain metastases. Cancer. https:\/\/doi.org\/10.1002\/cncr.25634","journal-title":"Cancer"},{"key":"1338_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/md14100175","author":"L De Matteis","year":"2016","unstructured":"De Matteis L et al (2016) Controlling properties and cytotoxicity of chitosan nanocapsules by chemical grafting. Mar Drugs. https:\/\/doi.org\/10.3390\/md14100175","journal-title":"Mar Drugs"},{"issue":"5","key":"1338_CR14","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.3390\/cancers12051198","volume":"12","author":"C Dianzani","year":"2020","unstructured":"Dianzani C, Monge C, Miglio G, Serpe L, Martina K, Cangemi L, Ferraris C, Mioletti S, Osella S, Gigliotti CL, Boggio E, Clemente N, Dianzani U, Battaglia L (2020) Nanoemulsions as delivery systems for poly-chemotherapy aiming at melanoma treatment. Cancers (Basel) 12(5):1198. https:\/\/doi.org\/10.3390\/cancers12051198","journal-title":"Cancers (Basel)"},{"issue":"11","key":"1338_CR15","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1586\/era.10.170","volume":"10","author":"E Erdei","year":"2010","unstructured":"Erdei E, Torres SM (2010) A new understanding in the epidemiology of melanoma. Expert Rev Anticancer Ther 10(11):1811\u20131823. https:\/\/doi.org\/10.1586\/era.10.170","journal-title":"Expert Rev Anticancer Ther"},{"key":"1338_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2018.07.054","author":"FNS Fachel","year":"2018","unstructured":"Fachel FNS et al (2018) Box-Behnken design optimization of mucoadhesive chitosan-coated nanoemulsions for rosmarinic acid nasal delivery\u2014in vitro studies. Carbohyd Polym. https:\/\/doi.org\/10.1016\/j.carbpol.2018.07.054","journal-title":"Carbohyd Polym"},{"key":"1338_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2020.104875","author":"FNS Fachel","year":"2020","unstructured":"Fachel FNS, Michels LR, Azambuja JH, Lenz GS, Gelsleichter NE, Endres M, Scholl JN, Schuh RS, Barschak AG, Figueir\u00f3 F, Bassani VL, Henriques AT, Koester LS, Teixeira HF, Braganhol E (2020) Chitosan-coated rosmarinic acid nanoemulsion nasal administration protects against LPS-induced memory deficit, neuroinflammation, and oxidative stress in Wistar rats. Neurochem Int. https:\/\/doi.org\/10.1016\/j.neuint.2020.104875","journal-title":"Neurochem Int"},{"issue":"5","key":"1338_CR19","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2018024697","volume":"35","author":"Y Fan","year":"2018","unstructured":"Fan Y et al (2018) Updated Progress of Nanocarrier-Based Intranasal Drug Delivery Systems for Treatment of Brain Diseases. Crit Rev Ther Drug Carrier Syst 35(5):433\u2013467. https:\/\/doi.org\/10.1615\/CritRevTherDrugCarrierSyst.2018024697","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"1338_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/cells9061412","author":"MG Ferraro","year":"2020","unstructured":"Ferraro MG et al (2020) Breast cancer chemotherapeutic options: a general overview on the preclinical validation of a multi-target Ruthenium(III) complex lodged in nucleolipid nanosystems. Cells. https:\/\/doi.org\/10.3390\/cells9061412","journal-title":"Cells"},{"key":"1338_CR22","doi-asserted-by":"publisher","unstructured":"Ho BN, Pfeffer CM, Singh ATK (2017) Update on Nanotechnology-based Drug Delivery Systems in Cancer Treatment 5981:5975\u20135981. https:\/\/doi.org\/10.21873\/anticanres.12044","DOI":"10.21873\/anticanres.12044"},{"issue":"33","key":"1338_CR21","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.18632\/oncotarget.27686.=","volume":"11","author":"GK In","year":"2020","unstructured":"In GK, Poorman K, Saul M, O\u2019Day S, Farma JM, Olszanski AJ, Gordon MS, Thomas JS, Eisenberg B, Flaherty L, Weise A, Daveluy S, Gibney G, Atkins MB, Vanderwalde A (2020) Molecular profiling of melanoma brain metastases compared to primary cutaneous melanoma and to extracranial metastases. Oncotarget 11(33):3118\u20133128. https:\/\/doi.org\/10.18632\/oncotarget.27686.=","journal-title":"Oncotarget"},{"issue":"6","key":"1338_CR23","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.2174\/1573413711107061014","volume":"7","author":"M Intakhab Alam","year":"2011","unstructured":"Intakhab Alam M et al (2011) Nanostructured lipid carrier containing CNS acting drug: formulation, optimization and evaluation. Curr Nanosci 7(6):1014\u20131027. https:\/\/doi.org\/10.2174\/1573413711107061014","journal-title":"Curr Nanosci"},{"issue":"1","key":"1338_CR24","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.carbpol.2013.01.072","volume":"94","author":"RAH Ishak","year":"2013","unstructured":"Ishak RAH et al (2013) A comparative study of chitosan shielding effect on nano-carriers hydrophilicity and biodistribution. Carbohyd Polym 94(1):669\u2013676. https:\/\/doi.org\/10.1016\/j.carbpol.2013.01.072","journal-title":"Carbohyd Polym"},{"issue":"2","key":"1338_CR25","doi-asserted-by":"publisher","first-page":"995","DOI":"10.3892\/or.2016.5342","volume":"37","author":"G Jiang","year":"2017","unstructured":"Jiang G et al (2017) Formulation of temozolomide-loaded nanoparticles and their targeting potential to melanoma cells. Oncol Rep 37(2):995\u20131001. https:\/\/doi.org\/10.3892\/or.2016.5342","journal-title":"Oncol Rep"},{"issue":"11","key":"1338_CR26","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1021\/acs.molpharmaceut.6b00586","volume":"13","author":"A Khan","year":"2016","unstructured":"Khan A et al (2016) Brain targeting of temozolomide via the intranasal route using lipid-based nanoparticles: brain pharmacokinetic and scintigraphic analyses. Mol Pharm 13(11):3773\u20133782. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6b00586","journal-title":"Mol Pharm"},{"key":"1338_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2015.08.022","author":"SS Kim","year":"2015","unstructured":"Kim SS et al (2015) Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma. Cancer Lett. https:\/\/doi.org\/10.1016\/j.canlet.2015.08.022","journal-title":"Cancer Lett"},{"issue":"613","key":"1338_CR28","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.bbrc.2022.05.003","volume":"12","author":"YS Kim","year":"2022","unstructured":"Kim YS, Shin S, Yin JH, Park J, Jung SH, Chung YJ (2022) Single-cell RNA sequencing reveals the existence of pro-metastatic subpopulation within a parental B16 murine melanoma cell line. Biochem Biophys Res Commun 12(613):120\u2013126. https:\/\/doi.org\/10.1016\/j.bbrc.2022.05.003","journal-title":"Biochem Biophys Res Commun"},{"key":"1338_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17091468","author":"DA Kircher","year":"2016","unstructured":"Kircher DA et al (2016) Melanoma brain metastasis: mechanisms, models, and medicine. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms17091468","journal-title":"Int J Mol Sci"},{"key":"1338_CR30","doi-asserted-by":"publisher","unstructured":"Kong L et al (2011) Melanoma in a murine model 16(9):2550\u20132561. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-0279.Inhibition","DOI":"10.1158\/1078-0432.CCR-10-0279.Inhibition"},{"key":"1338_CR31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.7837","author":"EL Korn","year":"2008","unstructured":"Korn EL et al (2008) Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2007.12.7837","journal-title":"J Clin Oncol"},{"key":"1338_CR32","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.5b00707","author":"F Lebre","year":"2016","unstructured":"Lebre F et al (2016) Intranasal Administration of Novel Chitosan nanoparticle\/DNA complexes induces antibody response to Hepatitis B surface antigen in Mice. Mol Pharm. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5b00707","journal-title":"Mol Pharm"},{"key":"1338_CR33","doi-asserted-by":"publisher","DOI":"10.1159\/000048381","author":"JYK Lee","year":"2000","unstructured":"Lee JYK et al (2000) Brain surgery with image guidance: current recommendations based on a 20-year assessment. Stereotact Funct Neurosurg. https:\/\/doi.org\/10.1159\/000048381","journal-title":"Stereotact Funct Neurosurg"},{"key":"1338_CR34","unstructured":"Li R-H et al (2015) Temozolomide for treating malignant melanoma. J Coll Phys Surg Pak 25(9): 680\u2013688. 09.2015\/JCPSP.680688"},{"issue":"7","key":"1338_CR35","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1038\/jid.2008.423","volume":"129","author":"E Linos","year":"2009","unstructured":"Linos E et al (2009) Increasing burden of melanoma in the United States. J Investig Dermatol 129(7):1666\u20131674. https:\/\/doi.org\/10.1038\/jid.2008.423","journal-title":"J Investig Dermatol"},{"key":"1338_CR36","first-page":"75","volume":"26","author":"A Matica","year":"2017","unstructured":"Matica A, Menghiu G, Ostafe V (2017) Biodegradability of chitosan based products. New Front Chem 26:75\u201386","journal-title":"New Front Chem"},{"key":"1338_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4470-y","author":"MA McDonald","year":"2018","unstructured":"McDonald MA et al (2018) Unmasking of intracranial metastatic melanoma during ipilimumab\/nivolumab therapy: case report and literature review. BMC Cancer. https:\/\/doi.org\/10.1186\/s12885-018-4470-y","journal-title":"BMC Cancer"},{"key":"1338_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.4615","author":"LR Michels","year":"2019","unstructured":"Michels LR, Fachel FNS, Azambuja JH, Gelsleichter NE, Braganhol E, Teixeira HF (2019) HPLC\u2013UV method for temozolomide determination in complex biological matrices: application for in vitro, ex vivo and in vivo studies. Biomed Chromatogr. https:\/\/doi.org\/10.1002\/bmc.4615","journal-title":"Biomed Chromatogr"},{"key":"1338_CR39","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.jconrel.2023.01.070","volume":"355","author":"LR Michels","year":"2023","unstructured":"Michels LR, Fachel FNS, Schuh RS, Azambuja JH, de Souza PO, Gelsleichter NE, Lenz GS, Visioli F, Braganhol E, Teixeira HF (2023) Nasal administration of a temozolomide-loaded thermoresponsive nanoemulsion reduces tumor growth in a preclinical glioblastoma model. J Control Release 355:343\u2013357. https:\/\/doi.org\/10.1016\/j.jconrel.2023.01.070","journal-title":"J Control Release"},{"issue":"2","key":"1338_CR40","doi-asserted-by":"publisher","first-page":"124","DOI":"10.2500\/ajra.2015.29.4149","volume":"29","author":"MM Miyake","year":"2015","unstructured":"Miyake MM, Bleier BS (2015) The blood-brain barrier and nasal drug delivery to the central nervous system. Am J Rhinol Allergy 29(2):124\u2013127. https:\/\/doi.org\/10.2500\/ajra.2015.29.4149","journal-title":"Am J Rhinol Allergy"},{"key":"1338_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12010213","author":"JM Pantshwa","year":"2020","unstructured":"Pantshwa JM et al (2020) Nanodrug delivery systems for the treatment of ovarian cancer. Cancers. https:\/\/doi.org\/10.3390\/cancers12010213","journal-title":"Cancers"},{"issue":"22","key":"1338_CR42","doi-asserted-by":"publisher","first-page":"7092","DOI":"10.1158\/1078-0432.CCR-09-1349","volume":"15","author":"J Portnow","year":"2009","unstructured":"Portnow J, Badie B, Chen M, Liu A, Blanchard S, Synold TW (2009) The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiation. Clin Cancer Res 15(22):7092\u20137098. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-1349","journal-title":"Clin Cancer Res"},{"key":"1338_CR43","doi-asserted-by":"publisher","unstructured":"Prego C et al (2005) Transmucosal macromolecular drug delivery. J Controll Release. https:\/\/doi.org\/10.1016\/j.jconrel.2004.07.030","DOI":"10.1016\/j.jconrel.2004.07.030"},{"key":"1338_CR44","unstructured":"Propet B (1994) Laboratory methods in histotechnology. laboratory manuals: manual of histologic staining methods of the Armed Forces Institute of Pathology. American Registry of Pathology, Washington, D.C. [viii, 279 p. : ill. (some col.) ; 26 cm]"},{"key":"1338_CR45","unstructured":"Riss TL et al (2004) Cell viability assays, assay guidance manual. In: Assay guidance manual. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23805433"},{"key":"1338_CR46","doi-asserted-by":"publisher","DOI":"10.4103\/ijdvl.ijdvl_791_19","author":"H Sabit","year":"2020","unstructured":"Sabit H, Kaliyadan F, Menezes R (2020) Malignant melanoma: underlying epigenetic mechanisms. Indian J Dermatol Venereol Leprol. https:\/\/doi.org\/10.4103\/ijdvl.ijdvl_791_19","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"1338_CR47","doi-asserted-by":"publisher","first-page":"4485","DOI":"10.3390\/cancers13174485","volume":"13","author":"V Soni","year":"2021","unstructured":"Soni V, Adhikari M, Simonyan H, Lin L, Sherman JH, Young CN, Keidar M (2021) In vitro and in vivo enhancement of Temozolomide effect in human glioblastoma by non-invasive application of cold atmospheric plasma. Cancers 13:4485. https:\/\/doi.org\/10.3390\/cancers13174485","journal-title":"Cancers"},{"key":"1338_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6673-2-16","author":"SS Suri","year":"2007","unstructured":"Suri SS, Fenniri H, Singh B (2007) Nanotechnology-based drug delivery systems. J Occup Med Toxicol. https:\/\/doi.org\/10.1186\/1745-6673-2-16","journal-title":"J Occup Med Toxicol"},{"key":"1338_CR49","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/647684","author":"F Tas","year":"2012","unstructured":"Tas F (2012) Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors. J Oncol. https:\/\/doi.org\/10.1155\/2012\/647684","journal-title":"J Oncol"},{"key":"1338_CR50","doi-asserted-by":"publisher","DOI":"10.1080\/07315724.2008.10719671","author":"NS Tapola","year":"2008","unstructured":"Tapola NS et al (2008) Safety aspects and cholesterol-lowering efficacy of chitosan tablets. J Am Coll Nutr. https:\/\/doi.org\/10.1080\/07315724.2008.10719671","journal-title":"J Am Coll Nutr"},{"key":"1338_CR51","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0b013e3283649a97","author":"F Teimouri","year":"2013","unstructured":"Teimouri F, Nikfar S, Abdollahi M (2013) Efficacy and side effects of dacarbazine in comparison with temozolomide in the treatment of malignant melanoma: a meta-analysis consisting of 1314 patients. Melanoma Res. https:\/\/doi.org\/10.1097\/CMR.0b013e3283649a97","journal-title":"Melanoma Res"},{"key":"1338_CR52","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3791\/54039","volume":"111","author":"JJ Timmons","year":"2016","unstructured":"Timmons JJ, Cohessy S, Wong ET (2016) (2016) \u2018Injection of syngeneic murine melanoma cells to determine their metastatic potential in the lungs.\u2019 J vis Exp 111:4\u20137. https:\/\/doi.org\/10.3791\/54039","journal-title":"J vis Exp"},{"issue":"4","key":"1338_CR53","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1517\/14740330902918281","volume":"8","author":"VA Trinh","year":"2009","unstructured":"Trinh VA, Patel SP, Hwu WJ (2009) The safety of temozolomide in the treatment of malignancies. Expert Opin Drug Saf 8(4):493\u2013499. https:\/\/doi.org\/10.1517\/14740330902918281","journal-title":"Expert Opin Drug Saf"},{"key":"1338_CR54","unstructured":"World Health Organization (2020) \u2018No Title\u2019. https:\/\/www.who.int\/uv\/resources\/FAQ\/skincancer\/en\/index2.html"},{"key":"1338_CR56","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19223","author":"GJ Young","year":"2017","unstructured":"Young GJ et al (2017) Management of intracranial melanomas in the era of precision medicine. Oncotarget. https:\/\/doi.org\/10.18632\/oncotarget.19223","journal-title":"Oncotarget"},{"key":"1338_CR57","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v5.i1.19","author":"W Zhu","year":"2014","unstructured":"Zhu W et al (2014) Temozolomide for treatment of brain metastases: A review of 21 clinical trials. World J Clin Oncol. https:\/\/doi.org\/10.5306\/wjco.v5.i1.19","journal-title":"World J Clin Oncol"}],"container-title":["Cellular and Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10571-023-01338-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10571-023-01338-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10571-023-01338-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T16:18:01Z","timestamp":1689005881000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10571-023-01338-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,13]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1338"],"URL":"https:\/\/doi.org\/10.1007\/s10571-023-01338-4","relation":{},"ISSN":["0272-4340","1573-6830"],"issn-type":[{"value":"0272-4340","type":"print"},{"value":"1573-6830","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,13]]},"assertion":[{"value":"9 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}